Robert Hasserjian

Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.

Research

Dr. Hasserjian's research interests include:

• Molecular mechanisms of leukemia and lymphoma.
• Novel pathologic, immunophenotypic, and molecular prognostic markers in myelodysplastic and myeloproliferative diseases, leukemias, and lymphomas

Medical Education

• MD, Harvard Medical School
• Residency, Brigham and Women's Hospital - Clinical Trainees
• Fellowship, Brigham and Women's Hospital - Clinical Trainees

American Board Certifications

• Anatomic Pathology, American Board of Pathology
• Pathology, American Board of Pathology

Publications

• Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle? Tandon B, Swerdlow SH, Hasserjian RP, Surti U, Gibson SE.Leuk Lymphoma. 2015 Apr 10:1-33.
• Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Nardi V, Pulluqi O, Abramson JS, Dal Cin P, Hasserjian RP. Am J Hematol. 2015 Mar 16.
• Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R. Bone Marrow Transplant. 2015 Feb 9. doi: 10.1038/bmt.2014.323.